A comparative review on mucocutaneous reactions caused by Covid‐19 infection versus Covid‐19 vaccination. Issue 8 (16th June 2022)

• Record Type: Journal Article
• Authors: Sadeghi, Sara; Amini, Zeynab; Goodarzi, Azadeh
• Is Part Of: Experimental dermatology. Volume 31:Issue 8(2022)
• Page Start: 1122
• Page End: 1127
• Publication Date: 2022-06-16
• Subjects: Covid‐19 -- mucosa -- reactions -- review -- skin -- vaccination; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/exd.14620
• Languages: English
• ISSNs: 0906-6705

Abstract

Abstract: The prevalence and severity of mucocutaneous manifestations in Covid‐19 infection are generally higher than those reported in Covid vaccines. Therefore, comparing the mucocutaneous reactions of the Covid‐19 infection and vaccination is necessary to enhance our knowledge about such reactions and guide us to evaluate the risk of infection or vaccination. A thorough literature search was conducted on PubMed, Google Scholar, and EBSCO (LISTA), and 2069 articles were downloaded. After screening, 11 studies remained for the final review. The literature review revealed that the prevalence and severity of postvaccine mucocutaneous adverse reactions have been less common compared to Covid‐19 infection. Postvaccine adverse reactions primarily occurred after the first dose administration and such reactions were manageable with antihistamines and corticosteroids administration. This comparative analysis highlights the frequency and potential severity of mucocutaneous reactions due to Covid‐19 infection and Covid‐19 vaccination. It also affirmed that potentially critical (serious) mucocutaneous reactions are more likely to occur in Covid‐19 infection compared to Covid vaccination. Moreover, postvaccine reactions predominantly happened after the first dose and were reported to be non‐life‐threatening, self‐manageable and with a lower incidence of potentially critical events. It was also concluded that the incidence of mucocutaneous reactions decreased in the following doses. Hence, given the low rate of such reactions following Covid‐19 vaccination, vaccines have a lower risk of mucocutaneous reactions occurrence than Covid‐19 infection. Further, due to the limited number of studies, we recommend that large‐scale trials evaluate such reactions comparing various types of Covid‐19 vaccines in healthy individuals and those with autoimmune skin disorders.